Hikma delivers a resilient underlying performance in 2022
2023-02-23
Amman, Jordan — Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its preliminary audited results for the year ended 31 December 2022. In 2022, the Group reported revenue of $2.517 billion (slightly down from $2.553 billion in 2021), backed by its resilient business model and goodContinue Reading